A closer look at “Merck's New Keytruda Formulation Blocked in Europe by Dutch Court Ruling”, exactly as the source publishes it. A Dutch court has ordered Merck to halt manufacturing and marketing of its new subcutaneous formulation of Keytruda in several European countries, dealing a blow to the pharmaceutical giant's plans for the blockbuster cancer drug. The ruling affects multiple European markets where the injectable version was set to launch, though the exact list of countries and the scope of the injunction were not detailed in the source.
The decision represents a significant setback for Merck, as the subcutaneous formulation was expected to offer patients a more convenient alternative to the current intravenous infusion of Keytruda, which generated over $25 billion in global sales last year. The court's action likely stems from a patent dispute, though specifics were not provided. For the complete material, the listing points back to the source inside the network.